Scott E Delacroix Jr M.D.

Medical Director Urologic Oncology/GU Cancers. Mary Bird Perkins Cancer Center. Metairie, Louisiana. Bladder and Prostate Cancer subspecialty.

[Scott E Delacroix Jr M.D. @UroCancer]

Radical Cystectomy shouldn't be the only conversation after EV-Pembro.

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

People have been DM and asking me: with an HR of 0.68 for durvalumab + BCG in POTOMAC, why isn’t this for every high-risk NMIBC patient?

Here’s how hazard ratios work – and why they can mislead you if you stop there. 🧵 #ASCO26

@tompowles1 @WesKassouf @shilpaonc @DrFelixGuerrero

[Pints Of Beauty @PintsBeauty]

36 years of loyal service and more cold beers than we could count.

RIP to a garage legend 🍻

[NRG Oncology @NRGonc]

Today on Clinical Trials Day, we honor patients, researchers & professionals advancing cancer care. Every study brings new hope. Thanks to all for helping to move oncology research forward. #ClinicalTrialsDay #CTD2026 #ResearchRising

[Scott E Delacroix Jr M.D. @UroCancer]

N=597

[NRG Oncology @NRGonc]

May is #BladderCancerAwarenessMonth. We're highlighting studies in our GU portfolio. NRG-GU015 The ARCHER Study is enrolling patients with cT2-cT3 MIBC that is clinically node negative. Learn more ➡️ https://t.co/paHFoF3qLZ @UroCancer @HimanshuNagarMD

[Brian F. Chapin @ChapinMD]

After 10 years as @UroOnc PD at @UTMDAnderson, Happy to announce @KKBree will assume the role

As APD, she has shown an unique ability 2 connect w/fellows while maintaining the rigor needed to train today’s Uro Oncs

Proud of her leadership + excited for the future #oncsurgery

[Scott E Delacroix Jr M.D. @UroCancer]

@tomboike @DietCoke Cans! Are you kidding me.
Does anyone actually drink the last couple sips out of a bottle? Have you tried the 16oz cans….

[Scott E Delacroix Jr M.D. @UroCancer]

@ChapinMD @Marriott @DietCoke Nope something to do with how the chickens are treated before they become and sandwich.

[Scott E Delacroix Jr M.D. @UroCancer]

#AUA2026 conference hotel with massive protest. Not just me that is upset about @Marriott still serving Diet Pepsi instead of @DietCoke

[Scott E Delacroix Jr M.D. @UroCancer]

@ysaralee @Marriott @DietCoke Chicken sandwich was excellent.

[Scott E Delacroix Jr M.D. @UroCancer]

@PCaParker @ChapinMD @DrSpratticus @Prof_Nick_James @NCCN @Uroweb @AmarUKishan @TylerSbrt @HimanshuNagarMD @seanmmcbride @ChrisSweens1 @ChadTangMD @piet_ost @_ShankarSiva @DrAndrewLoblaw One reason (not the only) —Progression within the first 6 months of starting SST. Two step enrollment (systemic litmus) with randomization after the 6 months. Correlatives gathered from day 1 though. N=patients randomized (not enrolled).

[Scott E Delacroix Jr M.D. @UroCancer]

That questions assumes patients aren’t on trial. NRG has a trial exactly for this. Patients are searching for multidisciplinary expertise beyond consolidative cystectomy. NRG GU015 (Archer) and SWOG 2427 (Bright) will help bring answer this. The trials are being done. In prostate —the trial is there—SWOG 1802….need enrollment to answer.

[NRG Oncology @NRGonc]

For #BladderCancerAwarenessMonth, we're highlighting NRG studies in our GU portfolio that are currently enrolling patients - NRG-GU014, The PARRC Trial is enrolling patients with high-grade T1 #bladdercancer. Learn more ➡️https://t.co/oibrOBJsJJ @BrianBaumannMD @UroCancer

[Tyler Seibert MD PhD @TylerSbrt]

Debate resulted in consensus: support clinical trials! We don’t know unless we investigate.

What an honor to discuss management of PSMA-only M1a #ProstateCancer with Jeff Karnes @CaPsurvivorship @UroCancer @DrSpratticus

#AUA26 @urogeek

[Philipp Dahm @EBMUrology]

My favorite slide from exciting #AUA26 crossfire discussion so far by @TylerSbrt on M1a PCA. Beware of indirect evidence. We have been burnt before.

[Scott E Delacroix Jr M.D. @UroCancer]

@Marriott what happened to the partnership with Coke? This Diet Pepsi just doesn’t cut it. #aua2026

[Neil Desai @ndesai2005]

@tompowles1 @montypal Q: Is there a reason why the chemoRT arm does not allow neoadj EVP? With 302/303 showing clear benefit of addition to local tx, the control arm of chemoRT alone feels handicapped. NRG GU15 and S2427 both allow EVP as SOC leading into CRT/IO-RT as example.

[Papa Heme @Papa_Heme]

@RayWangonc That’s not true. Most people are reasonable when their concerns are acknowledged in a polite and reasonable manner.